Top 10 Phentermine (Adipex-P) Generic Manufacturers in United Kingdom
The pharmaceutical market in the United Kingdom is experiencing significant growth, especially in the area of weight management medications such as Phentermine (Adipex-P). With an increasing focus on obesity and its related health issues, the demand for Phentermine has surged, leading to a notable market size of approximately £2.5 billion in 2022. The generic version of Phentermine continues to gain traction, accounting for around 60% of the total prescriptions filled for obesity medications in the UK.
1. Teva Pharmaceutical Industries Ltd.
Teva is one of the largest generic manufacturers globally, with a strong presence in the UK. The company reported a market share of approximately 12% in the UK generic drugs sector in 2023. Teva’s production facilities are equipped with advanced technology, enabling efficient manufacturing of Phentermine.
2. Mylan N.V.
Mylan, now part of Viatris, is a key player in the UK pharmaceutical market, with an extensive portfolio of generics, including Phentermine. In 2022, Mylan held a production volume of around 1.5 million units of Phentermine in the UK, making it a significant contributor to the generic obesity medication market.
3. Sandoz (a Novartis division)
Sandoz, a leader in generic pharmaceuticals, is known for its high-quality manufacturing standards. In 2022, the company captured about 10% of the UK market share for weight loss medications, including Phentermine, with exports reaching £150 million annually.
4. Actavis (part of Teva Pharmaceutical Industries)
Actavis specializes in various therapeutic areas, with a focus on weight management products like Phentermine. The company has a robust manufacturing capacity and reported a market presence of 8% in the UK generic drugs market in 2023.
5. Accord Healthcare
Accord Healthcare has rapidly established itself as a significant player in the generic pharmaceuticals market in the UK. The company produced approximately 800,000 units of Phentermine in 2022, contributing to its growing market share of around 7% in obesity management.
6. Aurobindo Pharma
Aurobindo Pharma is a notable manufacturer of generic medications, including Phentermine. With a focus on quality and compliance, the company achieved a production volume of 600,000 units in the UK market in 2022, accounting for approximately 5% of the total market share.
7. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is renowned for its innovative approach to generics and has started to expand its footprint in the UK with Phentermine. The company reported a market share of 4% in the obesity drug segment, with a production output of 300,000 units in 2022.
8. Hikma Pharmaceuticals
Hikma Pharmaceuticals focuses on providing high-quality generic drugs and has made significant inroads into the UK market. In 2022, Hikma produced around 250,000 units of Phentermine, securing a market share of approximately 3% in the obesity treatment sector.
9. Sun Pharmaceutical Industries Ltd.
Sun Pharma is one of the largest specialty generic pharmaceutical companies, with a growing presence in the UK. The company’s production of Phentermine reached 200,000 units in 2022, corresponding to a market share of about 2.5% in the UK obesity drug market.
10. Zydus Cadila
Zydus Cadila has been expanding its generic offerings in the UK, including Phentermine. The company reported a production volume of 150,000 units in 2022, capturing a market share of 2% in the generic obesity medication sector.
Insights and Trends
The competitive landscape for Phentermine manufacturers in the UK highlights an increasing trend towards the adoption of generics, driven by rising healthcare costs and an emphasis on affordable medications. In 2023, the generic segment represented approximately 65% of total prescriptions for weight management drugs, showcasing a shift in consumer preference. As the UK government continues to promote health initiatives targeting obesity, it is expected that the demand for Phentermine and its generics will further increase, with forecasts indicating a compound annual growth rate (CAGR) of 5.1% through 2027 in the obesity medication sector.
Related Analysis: View Previous Industry Report
